4Breed FC,Dayer JM.Leflunomide:mode of action in treatment of rheumatoid arthritis[J].Ann Rheum Dis,2000,59(1):841-849
5Manna SK,Aggarwal BB.Immunosuppressive lefunomide metabolite (A771726) blocks TNF-dependent muclear factor-kappa B activation and gene expression[J].J Immunol,1999,162(4):2095-2102
6Dimitrora P,Skapenko A,Schleyerbach R.Immunomodulatory fu-nctions of leflunomide:inhibition of Th1 cell activation and promotion of Th2 differentiation[J].Arthritis Rheum,2001,44(suppl):216
7Kessel A,Toubi E.Leflunomide in systemic lupus erythematosus[J].Harefuah,2002,141(4):355-357,409
8MII J S J A, MICHEL B A, BLOCH D A, et al. The American Col- lege of Rheumatolagy 1990 criteria for the classification of Henoch-Schonlein purpura [ J ]. Arthritis Rheum, 1990, 33 ( 8 ): 1114-1121.
9RONKAINEN J, KOSKIMIES O, ALA-HOUHAIA M, et al. Early Prednisone therapy. In Henoch-Schonlein purpura: a randomized, double-blind, placebo-controlled [ J ]. Trim Pediatr, 2006, 1499 (2) ~ 241-247.
10FLOCCARI F, PALLA R, POLITO P, et al. Intravenous im- munoglobulin in the treatment of glomerulopathies [ J ]. Ital Ne- fml,2007,24(4) :311-319.
